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Abstract	
Trace	Amine-Associated	Receptor	1	 (TAAR1)	 is	a	G	protein-coupled	receptor	expressed	 in	 the	
mammalian	 brain	 and	 known	 to	 influence	 subcortical	 monoaminergic	 transmission.	
Monoamines,	such	as	dopamine,	play	also	an	important	role	within	the	prefrontal	cortex	(PFC)	
circuitry,	which	 is	critically	 involved	 in	high	order	cognitive	processes.	TAAR1	selective	 ligands	
have	 shown	potential	 antipsychotic,	 antidepressant	 and	pro-cognitive	effects	 in	experimental	
animal	 models;	 however,	 it	 remains	 unclear	 if	 TAAR1	 can	 affect	 PFC-related	 processes	 and	
functions.	In	this	study,	we	document	distinct	pattern	of	expression	of	TAAR1	in	the	mouse	PFC,	
as	well	as	altered	subunit	composition	and	deficient	functionality	of	the	glutamate	N-methyl-D-
aspartate	(NMDA)	receptors	in	the	pyramidal	neurons	of	layer	V	of	PFC	in	mice	lacking	TAAR1.	
The	 dysregulated	 cortical	 glutamate	 transmission	 in	 TAAR1-KO	 mice	 was	 associated	 with	
aberrant	 behaviors	 in	 several	 tests,	 indicating	 a	 perseverative	 and	 impulsive	 phenotype	 of	
mutants.	 Conversely,	 pharmacological	 activation	 of	 TAAR1	 with	 selective	 agonists	 reduced	
premature	impulsive	responses	observed	in	the	fixed-interval	conditioning	schedule	in	normal	
mice.	 Our	 study	 indicates	 that	 TAAR1	 plays	 an	 important	 role	 in	 the	 modulation	 of	 NMDA	
receptor-mediated	 glutamate	 transmission	 in	 the	 PFC	 and	 related	 functions.	 Furthermore,	
these	data	suggest	that	development	of	TAAR1-based	drugs	could	provide	a	novel	therapeutic	
approach	for	the	treatment	of	disorders	related	to	aberrant	cortical	functions.	
	
	
	
Introduction	
Trace	Amine-Associated	Receptor	1	 (TAAR1)	 is	 a	G	protein-coupled	 receptor	 (GPCR)	 found	 in	
several	regions	of	the	mammalian	brain	with	the	highest	expression	observed	in	the	subcortical	
monoaminergic	nuclei,	such	as	the	ventral	tegmental	area	(VTA)	and	the	dorsal	raphe,	whereas	
low	 levels	 are	 detected	 in	 the	 striatum	and	 several	 other	 brain	 areas	 (Borowsky	 et	 al,	 2001;	
Bunzow	et	al,	2001;	Di	Cara	et	al,	2011;	Lindemann	et	al,	2008).	Recently,	TAAR1	functions	have	
been	extensively	characterized,	with	particular	attention	paid	 to	 its	 role	 in	 the	modulation	of	
the	midbrain	dopamine	system	and	 its	possible	 implications	 in	psychiatric	diseases	(Borowsky	
et	al,	2001;	Bunzow	et	al,	2001;	Leo	et	al,	2014;	Lindemann	and	Hoener,	2005;	Sotnikova	et	al,	
2009;	Sukhanov	 et	al,	2014).	TAAR1	knockout	 (TAAR1-KO)	mice	display	a	higher	 sensitivity	 to	
amphetamine	and	other	psychostimulants	(Di	Cara	et	al,	2011;	Lindemann	et	al,	2008;	Wolinsky	
et	al,	2007),	and	seem	to	have	a	supersensitive	dopaminergic	system	(Lindemann	et	al,	2008;	
Wolinsky	et	al,	2007),	making	them	an	interesting	model	relevant	for	schizophrenia	(Wolinsky	
et	 al,	 2007).	 Accordingly,	 both	 full	 and	 partial	 TAAR1	 selective	 agonists	 are	 efficacious	 in	
experimental	rodent	models	of	psychosis,	such	as	pharmacologic	or	genetic	mouse	models	of	
hyperdopaminergia,	further	supporting	the	idea	that	TAAR1	could	represent	a	novel	target	for	
psychiatric	diseases	(Espinoza	and	Gainetdinov,	2014;	Sotnikova	et	al,	2009).	Although	there	is	
evidence	suggesting	a	potential	TAAR1	 involvement	 in	cognitive	 functions	 (Revel	 et	al,	2013),		
no	 studies	 evaluated	 TAAR1	 role	 in	 cortical	 regions	 so	 far.	 Recently,	 it	 has	 been	 shown	 that	
TAAR1	agonists	were	able	to	suppress	hyperactivity	in	pharmacologic	or	genetic	mouse	models	
of	 glutamate	 NMDA	 receptor	 deficiency	 and	 improved	 cognition	 in	 rats	 treated	 with	 the	
glutamate	NMDA	receptor	antagonist	phencyclidine	(PCP)	(Revel	et	al,	2013).		Intriguingly	also,	
TAAR1	agonists,	 tested	 in	phMRI	 studies	 in	mice,	 shared	a	 similar	pattern	of	brain	 activation	
with	 the	 antipsychotic	 olanzapine	with	 the	most	 prominent	 activation	 being	 observed	 in	 the	
medial	PFC	(Revel	et	al,	2013).		
Thus,	the	aim	of	this	study	was	to	investigate	the	role	of	TAAR1	in	the	prefrontal	cortex	(PFC),	a	
brain	 region	 important	 for	 cognitive	 functions.	 In	 particular,	 we	 explored	 if	 TAAR1	 might	
modulate	 cortical	 glutamatergic	 transmission	 since	 its	 deficiency	 is	 implicated	 in	 the	
pathophysiology	of	schizophrenia	(Millan	et	al,	2012),	which	postulates,	among	other	theories,	
involvement	of	NMDA	receptor	hypofunction	(Mohn	et	al,	1999).	
Materials	and	methods	
Animals	
	TAAR1	knockout	 (TAAR1-KO)	mice	of	mixed	C57BL/6J	x	129Sv/J	backgrounds	were	generated	
as	previously	described	(Wolinsky	et	al,	2007).	Animal	care	and	treatments	were	performed	in	
accordance	with	the	Guide	for	the	Care	and	Use	of	Laboratory	Animals	(USA	National	Institutes	
of	Health	publication	#865-23,	Bethesda,	MD),	and	the	protocols	were	approved	by	the	Italian	
Ministry	of	Health.	All	TAAR1-KO	and	WT	littermates	were	obtained	from	heterozygous	mating,	
and	genotyping	was	performed	in	all	individuals.	Mice	of	8-16	weeks	of	age	and	of	both	sexes	
were	used	in	all	experiments.	Mice	were	sex	and	age	matched	in	all	experiments.		
	
Western	blot	
The	crude	synaptosomal	fraction	was	obtained	from	the	PFC	extracts	to	evaluate	glutamatergic	
receptor	 expression	 and	 composition	 (Fumagalli	 et	 al,	 2012).	 The	PFC	was	homogenized	 in	 a	
glass-glass	potter	using	a	cold	buffer	containing	0.32	M	sucrose,	1	mM	Hepes	solution,	0.1	mM	
EGTA,	 and	 0.1	 mM	 PMSF,	 pH=7.4,	 in	 the	 presence	 of	 a	 complete	 set	 of	 protease	 inhibitors	
(Sigma-Aldrich,	 Milan,	 Italy)	 and	 a	 phosphatase	 inhibitor	 cocktail	 (Sigma-Aldrich).	 The	
homogenized	 tissues	 were	 centrifuged	 at	 1000	 g	 for	 10	 min;	 the	 resulting	 supernatant	 was	
centrifuged	at	9000	g	for	15	min	to	obtain	the	pellet	corresponding	to	the	crude	synaptosomal	
fraction,	which	was	resuspended	in	a	buffer	containing	20	mM	Hepes,	0.1	mM	DTT,	and	0.1	mM	
EGTA	 in	 the	 presence	 of	 a	 complete	 set	 of	 protease	 inhibitors	 and	 a	 phosphatase	 inhibitor	
cocktail.	Ten	micrograms	of	proteins	 for	each	sample	were	 run	on	a	SDS-10%	polyacrylamide	
gel	 under	 reducing	 conditions	 and	 then	 electrophoretically	 transferred	 onto	 nitrocellulose	
membranes	 (GE	 Healthcare,	 Milan,	 Italy).	 Blots	 were	 incubated	 with	 antibodies	 against	 the	
phosphorylated	forms	of	the	proteins	and	actin	was	used	as	loading	control.	Immunocomplexes	
were	 visualized	 by	 chemiluminescence	 using	 the	 Chemidoc	 MP	 Imaging	 System	 (Bio-Rad	
Laboratories).		
	
Real	time	PCR	
Real	time	PCR	was	performed	as	described	in	SI	Materials	and	Methods.	
	
Electrophysiology	recordings	
Preparation	of	slices	
For	all	patch-clamp	experiments,	we	used	3-5	week-old	wild-type	and	TAAR1-KO	mice.	Coronal	
slices	containing	the	mPFC	(350	μm	thickness)	were	cut	using	a	Microm	HM	650V	microtome	
provided	with	a	Microm	CU	65	cooling	unit	(both	Thermo	Fisher	Scientific,	Waltham	MA,	USA).	
Slices	 were	 cut	 at	 2°C	 in	 a	 solution	 containing	 (mM):	 87	 NaCl,	 25	 NaHCO3,	 2.5	 KCl,	 1.25	
NaH2PO4,	0.5	CaCl2,	7	MgCl2,	25	glucose,	and	75	sucrose	saturated	with	95%	O2	and	5%	CO2.	
After	 cutting,	 we	 recovered	 the	 slices	 for	 30-45	minutes	 at	 35°C	 and	 for	 one	 hour	 at	 room	
temperature	 in	 the	 recording	 solution.	 The	 physiological	 extracellular	 solution	 used	 for	
recordings	containing	(mM):	125	NaCl,	25	NaHCO3,	25	glucose,	2.5	KCl,	1.25	NaH2PO4,	2	CaCl2,	
and	 1	 MgCl2	 (bubbled	 with	 95%	 O2-5%	 CO2).	 For	 all	 experiments,	 we	 used	 an	 intracellular	
solution	 containing	 (in	 mM):	 126	 K	 gluconate,	 4	 NaCl,	 1	 MgSO4,	 0.02	 CaCl2,	 0.1	 BAPTA,	 15	
Glucose,	5	HEPES,	3	ATP	and	0.1	GTP.	The	pH	was	adjusted	to	7.3	with	KOH,	and	the	osmolarity	
was	adjusted	to	290	mosmol	l−1	with	sucrose.	
Patch-clamp	recordings	
Neuronal	firing	activity	and	excitatory	postsynaptic	currents	(EPSCs)	were	studied	by	whole-cell	
current-clamp	 and	 voltage-clamp	 recordings.	 All	 experiments	 were	 performed	 on	
morphologically	identified	layer	V	pyramidal	neurons.	Both	approaches	were	performed	using	a	
Multiclamp	700B	amplifier	 (Axon	 Instruments,	Molecular	Devices,	Sunnyvale	CA,	USA)	and	an	
upright	 BX51WI	 microscope	 (Olympus,	 Japan)	 equipped	 with	 Nomarski	 optics.	 For	 the	
extracellular	stimulation	of	layers	II-III,	we	used	a	bipolar	tungsten	electrode	(intensity:	50-150	
μA,	 duration:	 30	 μs)	 connected	 to	 an	 isolated	 pulse	 stimulator	 (A-M	 Systems,	 Carlsborg	WA,	
USA).	Patch	electrodes,	fabricated	from	thick	borosilicate	glasses,	were	pulled	and	fire-polished	
to	 a	 final	 resistance	 of	 5-7	 MΩ.	 Recordings	 with	 either	 leak	 currents	 >100	 pA	 or	 a	 series	
resistance	>15	MΩ	were	discarded.	Experiments	were	performed	at	22–24	°C.	For	the	isolation	
of	EPSCs	 in	 the	voltage-clamp	configuration,	Bicuculline	 (30	µM)	and	CGP58845	 (5	µM)	were	
added	to	the	extracellular	solution.	For	the	recording	of	miniature	NMDA	PSCs,	TTX	(300	nM),	
CNQX	 (10	 µM),	 Bicuculline	 (30	µM),	 and	 CGP58845	 (5	 µM)	 were	 added	 to	 the	 extracellular	
solution.	Moreover,	the	extracellular	Ca2+/Mg2+	ratio	was	changed	(2.5	mM	CaCl2	and	0.5	mM	
MgCl2)	to	avoid	the	Mg2+	block	of	NMDA	receptors.	
	
Peak	interval-fixed	interval	behavioral	assay		
Apparatus	and	procedure	
In	this	study,	we	used	a	device	called	COWE	(Cognition	and	Welfare),	which	was	developed	by	
TSE	 Systems	 (Germany)	 on	 the	 basis	 of	 the	 PhenoMaster	 System	 (Urbach	 et	 al,	 2010)	 and	
consists	of	an	operant	wall	located	in	the	home	cage.	The	operant	wall	has	three	hopper/holes	
with	infrared	beams	that	detect	the	nose-poke	activity,	but	in	this	case,	we	blocked	one	lateral	
hopper	and	we	used	two	hoppers,	one	next	to	the	other.	The	right	hole	was	the	control	hopper,	
while	the	left	hole	was	connected	to	a	food	dispenser/feeder	that	released	20	mg	of	dustless	
precision	 pellets	 (BioServ,	 USA).	 Each	 hole	 was	 equipped	 with	 a	 small	 LED	 with	 4	 mcd	
(millicandela)	of	luminous	intensity	that	was	remotely	controlled	via	computer,	as	it	was	for	the	
infrared	 beams	 and	 feeder.	 The	 TSE	 Systems-OBS	 software	 was	 used	 to	 design	 trial-by-trial	
protocols	 for	 group	 cages.	 The	 animals	 were	 kept	 in	 light-controlled,	 sound	 proof	 and	
ventilated	cubicles.	The	cubicle	light	(100-110	lux)	was	set	to	switch	on	at	7	a.m.	and	to	switch	
off	at	7	p.m.		
Experimental	design	
Before	starting	the	experiments,	the	animals	were	singly	housed	and	adapted	to	the	precision	
pellets	with	food	restriction	for	two	days.	The	experiment	consisted	of	a	Pre-Training	phase	and	
a	Training	phase.	In	the	Pre-Training	phase,	the	mice	self-initiated	the	trial	by	poking	in	the	right	
hopper,	determining	the	illumination	of	the	two	holes.	The	animals	were	required	to	nose	poke	
(NP)	in	the	left	hopper	after	the	light	signal	went	off	(L=2	sec)	to	receive	a	pellet	reward.	During	
this	 phase,	 the	 animals	 learned	 the	 association	between	 the	 left	 hopper	 and	 the	 feeder.	 For	
each	trial,	there	was	a	30	sec	time	limit	within	which		mice	could	receive	a	reward.	At	the	end	of	
each	 trial,	 the	 Inter	 Trial	 Interval	 (ITI)	 began,	 which	 was	 the	 sum	 of	 a	 fixed	 interval	 of	 30	
seconds	 and	 a	 random	 interval	 coming	 from	 a	 geometric	 distribution	 with	 a	 mean	 of	 60	
seconds.	This	phase	lasted	3	days.	The	Training	phase	consisted	of	a	variant	of	the	Peak	Interval	
(PI)	 timing	 procedure	 with	 80%	 Fixed-Interval	 (FI)	 trials	 and	 20%	 unreinforced	 probe	 trials.	
During	the	FI	trials,	the	mice,	as	in	the	Pre-Training	phase,	self-initiated	the	trial	by	poking	in	the	
right	 hopper	 (R),	 determining	 the	 illumination	 of	 the	 two	 holes.	 After	 two	 seconds	 (L=2	 sec)	
from	the	beginning	of	the	trials,	the	lights	switched	off,	and	only	after	ten	seconds	(T=10	sec),	a	
pellet	reward	was	delivered	in	response	to	a	NP	in	the	left	hopper	(L).	Any	NP	before	10	sec	had	
no	 consequence,	 and	 any	NP	 after	 the	 time	 limit	 (30	 sec)	was	 not	 reinforced.	 The	 ITI	 began	
after	the	release	of	the	pellet	or	at	the	end	of	the	time	limit.	Twenty	percent	of	the	probe	trials	
(Lp)	were	 randomly	 intermixed	with	 the	 normal	 trials	 and	were	 identical	 to	 the	 FI	 trials,	 but	
without	payoff.	This	phase	lasted	5	days.	
For	Data	Analysis,	see	SI	Materials	and	Methods.	
	
Schedule	of	a	reinforcement	Fixed	Interval	30	sec	in	mice	
Apparatus.		
	Standard	 operant	 conditioning	 chambers	 (MED	 Associates,	 Inc.,	 East	 Fairfield,	 VT)	 were	
enclosed	within	 sound-attenuating	 ventilated	 cubicles,	 connected	 to	 a	 computer	 through	 an	
interface	 and	 controlled	 by	MED-PC	 software.	 Chambers	were	 equipped	with	 a	white	 house	
light	centered		10	cm	above	the	nose-poke	manipulanda	(positioned	2	cm	above	the	floor)	and	
a	food	dispenser,	which	delivered	14-mg	food	pellets	(5TUL	–	1811215	IPS	Product	Supplies	Ltd,	
London,	ENG).	
Pre-Training.			
Male	8-week	old	C57BL/6J	mice	and	additional	group	of	WT	and	TAAR1-KO	mice	were	deprived	
of	 food	and	 trained	 to	nose	poke	 for	 food	during	 two	consecutive	daily	 sessions	 (habituation	
and	magazine	training).	
Training.		
Mice	 were	 trained	 to	 nose	 poke	 for	 food	 pellet	 delivery	 according	 to	 a	 fixed-ratio	 1	 (FR1)	
schedule	of	reinforcement.	Only	one	nose	poke	in	each	box	was	active.	A	response	in	this	nose	
poke	 was	 recorded	 (correct	 response)	 and	 rewarded	 by	 the	 delivery	 of	 one	 food	 pellet.	 A	
response	 in	 a	 different	 nose	 poke	 was	 scored	 as	 an	 incorrect	 response,	 but	 did	 not	 have	
programmed	consequences.	The	left-right	locations	of	the	active	and	inactive	nose	pokes	were	
counterbalanced	 in	the	mice.	The	position	of	active	nose	pokes	for	each	mouse	was	constant	
for	the	duration	of	the	experiment.	The	criterion	for	nose-poke	response	acquisition	 included	
50	reinforcements	earned	during	the	30-min	session.			
FI	schedule.		
	After	 mice	 acquired	 the	 nose-poke	 response	 (4	 days),	 the	 Fixed-Interval	 3	 sec	 (FI-3	 sec)	
schedule	was	started.	The	FI	 schedule	of	 reinforcement	 involved	delivering	 reinforcement	 for	
the	first	response	after	a	specific	period	of	time	had	elapsed.	In	the	FI-3	sec,	a	correct	response	
before	 3	 seconds	 after	 the	 previous	 delivery	 of	 reinforcement	 expired	 was	 scored	 as	 a	
premature	correct	response	but	did	not	have	programmed	consequences.	The	FI	schedule	was	
gradually	increased:	FI-5	sec,	FI-8	sec,	FI-12	sec,	FI-18	sec,	FI-24	sec,	and	FI-30	sec.	The	duration	
of	 the	 session	was	 limited	 to	 60	minutes.	 Subjects	 received	 one	 session	 per	 day.	 Drug	 tests	
were	started	when	the	mice	stabilized	their	behavior,	showing	less	than	20%	variability	during	
the	last	two	days	before	the	test.	
Drug	tests.			
RO5166017	 (0.1-1.0	 mg/kg)	 and	 RO5203648	 (0.03-0.3	 mg/kg)	 were	 dissolved	 in	 saline	 with	
minimal	amounts	of	Tween	80	and	administered	i.p.	 in	a	10	ml/kg	 injection	volume.	All	drugs	
were	given	30	min	prior	 to	 the	 test	session.	 In	 the	FI	 test,	different	doses	were	 tested	 in	 the	
order	derived	from	a	Latin	square	design.	
Data	analysis.		
	The	primary	dependent	variables	were	the	number	of	premature	correct	nose-poke	responses	
and	 the	post-reinforcement	pause	 (time	between	 last	 reinforced	 correct	nose-poke	 response	
and	 next	 correct	 nose-poke	 response).	 Additional	 analysis	 was	 conducted	 on	 the	 number	 of	
nose	pokes	in	the	food	tray.	
	
Results	
Expression	of	TAAR1	in	cortical	neurons	
VTA	dopaminergic	 neurons	 project	 to	 different	 subregions	 of	 the	 PFC,	making	 synapses	with	
glutamate	and	GABA	neurons	located	in	different	layers	(Tritsch	and	Sabatini,	2012).	TAAR1	is	
expressed	in	VTA	dopaminergic	neurons,	and	according	to	some	preliminary	reports,	it	might	be	
found	in	the	frontal	cortex	(Di	Cara	et	al,	2011;	Lindemann	et	al,	2008).	To	understand	the	role	
that	 TAAR1	 could	 have	 in	 this	 region,	 we	 first	 evaluated	 its	 expression	 in	 the	 PFC	 of	 adult	
animals.	Using	RT-PCR,	we	determined	that	TAAR1	mRNA	is	 indeed	found	in	the	PFC,	with	no	
signal	 detected	 in	 TAAR1-KO	 animals	 (Fig.	 S1).	 We	 also	 measured	 TAAR1	 transcript	 in	
adolescent	 mice	 (1	 month	 old),	 to	 evaluate	 the	 whether	 TAAR1	 is	 differentially	 expressed	
during	the	development.	As	shown	in	Fig.	S1,	both	adolescent	and	adult	animals	express	similar	
levels	of	TAAR1	transcript.	Furthermore,	to	investigate	the	precise	localization	of	TAAR1	in	this	
area,	we	used	a	recently	developed	transgenic	rat	model,	TAAR1	KO/dsRed	knock	in	rats,	where	
fluorescent	 marker	 dsRed	 was	 expressed	 under	 TAAR1	 promoter	 (Harmeier	 and	 Hoener;	
manuscript	 in	preparation).	 By	using	 this	 novel	 tool	 that	 allows	both	 the	 investigation	of	 the	
consequences	 of	 the	 lack	 of	 TAAR1	 in	 rats	 and	 the	 reliable	 mapping	 of	 TAAR1	 expression	
pattern,	we	 found	a	distinct	 fluorescent	 signal	 in	 layer	V	 cortical	neurons	 in	 general	 and	PFC	
specifically	 (Fig.	1A,	 right	panel,	bottom).	 	No	signal	was	detected	 in	other	 layers	of	cortex	of	
transgenic	rats	and	any	region	of	WT	animals	(Fig.	1A,	right	panel,	top).		Taken	together,	these	
observations	indicate	a	significant	expression	of	TAAR1	in	rodent	prefrontal	cortex	neurons.	
	
Deficient	glutamate	NMDA	receptors	function	in	the	mPFC	layer	V	pyramidal	neurons	of	
TAAR1-KO	mice		
To	further	evaluate	the	role	of	TAAR1	in	this	area	we	applied	patch-clamp	electrophysiological	
approach	 to	 cortical	 slices.	 First,	 we	 analyzed	 the	 impact	 of	 TAAR1	 deletion	 on	 the	 intrinsic	
neuronal	 excitability	 of	 layer	 V	 pyramidal	 neurons	 in	 the	mPFC	 (Fig.	 1A,	 left	 panel).	 For	 this	
purpose,	 we	 used	 the	 patch-clamp	 method	 in	 the	 current-clamp	 configuration,	 and	 we	
measured	the	output	of	the	wild	type	(WT)	and	TAAR1-KO	mPFC	neurons	in	response	to	current	
injection	 steps	 (Fig.	 1C).	 The	 injection	 of	 current	 did	 not	 modify	 the	 action	 potential	 firing	
frequency	 in	TAAR1-KO	neurons	with	 respect	 to	WT	neurons	 (Fig.	1B,	C),	 and	 it	did	not	alter	
other	parameters	of	neuron	excitability	(Fig.	1D).	However,	the	membrane	resting	potential	in	
TAAR1-KO	 neurons	 was	 more	 depolarized	 compared	 to	 WT	 neurons	 (Fig.	 1C),	 suggesting	 a	
potential	effect	at	the	level	of	synaptic	contacts	in	the	dendritic	tree	of	these	neurons.	Synaptic	
inputs	 on	 pyramidal	 neurons	 are	 important	 for	 the	 signal	 integration	 that	 elicits	 an	 action	
potential;	 thus,	 the	 next	 step	 was	 to	 analyze,	 in	 detail,	 the	 excitatory	 synaptic	 strength	 of	
TAAR1-KO	 mPFC	 neurons.	 After	 extracellular	 stimulation	 of	 layers	 II-III	 of	 the	 mPFC	 with	 a	
bipolar	 tungsten	 electrode,	 we	 found	 that	 the	 amplitude	 of	 excitatory	 postsynaptic	 currents	
(EPSCs)	 is	 increased	 in	 TAAR1-KO	 neurons	 (Fig.	 1E,	 F).	 Moreover,	 the	 kinetics	 of	 EPSCs	 was	
altered	 in	 the	TAAR1-KO	neurons	 (Fig.	1F),	 suggesting	possible	changes	 in	 the	composition	of	
postsynaptic	glutamatergic	receptors.	
To	investigate	which	postsynaptic	receptor	subtypes	could	be	involved	in	the	alteration	of	EPSC	
kinetics	 in	TAAR1-KO	mPFC	neurons,	we	analyzed	the	NMDA/AMPA	ratio	 in	the	mPFC	layer	V	
pyramidal	neurons	upon	stimulation	of	the	layer	III	neuron	fibers.	We	found	that	this	ratio	was	
altered	in	TAAR1-KO	neurons	(Fig.	2A,	B),	most	likely	due	to	a	reduction	of	the	NMDA	currents.	
To	 test	 this	 hypothesis,	we	performed	miniature	NMDA	excitatory	 postsynaptic	 currents	 and	
found	 a	 strong	 decrease	 in	 both	 the	 amplitude	 and	 the	 frequency	 of	 these	 currents	 in	 the	
TAAR1-KO	 neurons	 (Fig.	 2C-E).	 These	 data	 indicate	 the	 NMDA	 receptor-dependent	 synaptic	
deficits	in	mPFC	layer	V	pyramidal	neurons	of	mice	lacking	TAAR1.				
	
Glutamate	NMDA	receptor	composition	is	altered	in	the	prefrontal	cortex	of	TAAR1-KO	mice	
NMDA	 receptors	 are	 hetero-tetramers	 formed	 from	 the	 assemblies	 of	 GluN1	 subunits	 with	
GluN2A-D	and	GluN3A/B	(Collingridge	et	al,	2013).	Thus,	to	study	the	molecular	determinants	
responsible	 for	 the	 alterations	 seen	 in	 electrophysiological	 experiments,	 we	 evaluated	 the	
expression	 of	 several	 proteins	 that	 are	 critical	 for	 glutamate	 synapses	 in	 the	 synaptosomal	
fraction	 of	 the	 PFC	 of	 adult	 WT	 animals	 and	 their	 KO	 littermates	 by	 using	 Western	 blot	
approach.	 In	 these	experiments	we	 found	a	decrease	 in	 the	expression	of	 the	GluN1	 subunit	
(Fig.	3A),	as	well	as	a	decrease	 in	the	phosphorylation	of	GluN1	at	serine	896	(Fig.	3A),	 in	the	
PFC	 of	 TAAR1-KO	 mice.	 No	 changes	 in	 the	 serine	 897	 residue	 of	 the	 same	 subunit	 were	
observed	(Fig.	3A).	Furthermore,	a	decrease	in	the	expression	of	GluN2B	was	also	documented	
(Fig.	3B),	with	no	changes	observed	in	phospho-GluN2B	(serine	1303)	(Fig.	3B)	or	GluN2A	levels	
(Fig.	 3B).	 In	 contrast	 to	GluN1	and	GluN2B	NMDA	 receptor	 subunits,	AMPA	 receptor	 subunit	
GluA1	 levels	 and	phosphorylation	 status	 (Serine	831)	were	not	 changed	 in	mutants	 (Fig.	 3C).	
Similarly,	 the	 levels	 of	 PSD-95,	 a	 postsynaptic	 protein	 critically	 involved	 in	 the	 proper	
organization	 of	 postsynaptic	 structure	 and	 integrity	 (Gardoni	 and	 Di	 Luca,	 2006),	 were	 not	
altered	 by	 TAAR1	 deficiency	 (Fig.	 3C).	 These	 data	 demonstrate	 significant	 alterations	 in	 the	
composition	 of	 cortical	 NMDA	 receptors	 further	 supporting	 NMDA	 receptor	 dysfunction	
observed	in	the	PFC	of	TAAR1-KO	mice	in	electrophysiological	experiments.	In	addition,	to	test	
if	 TAAR1	 activation	 could	 modulate	 NMDA	 activity	 acutely,	 we	 used	 another	 experimental	
approach	by	using	cultured	cortical	neurons.	Cultured	neurons	were	treated	with	RO5166017	at	
1µM	or	vehicle	and	the	expression	of	GluN1	and	its	phosphorylation	site	S896	was	assessed	by	
western	blot.	As	shown	in	Fig.	S2,	RO5166017	produce	a	modest	increase	in	GluN1	expression	
but	 a	 significantly	 increase	 in	 the	 phosphorylation	 of	 S896,	 suggesting	 that	 TAAR1	 can	
influences	NMDA	activity	acutely.	
	
Lack	of	TAAR1	leads	to	perseverative	and	impulsive	behaviors	
To	unveil	 the	behavioral	 consequences	of	TAAR1	deficiency	 leading	 to	altered	cortical	NMDA	
receptor	 function,	 we	 first	 evaluated	 the	 cognitive	 functions	 of	 TAAR1-KO	 mice	 in	 a	 Fixed	
Interval-Peak	 Interval	 test	 (Matell	 and	 Meck,	 2000).	 The	 automated	 protocols	 allowed	 the	
testing	of	mice	in	home	cages	for	24	hours	per	day	for	several	days	to	collect	a	massive	amount	
of	 data	 with	 less	 variability	 by	 monitoring	 mouse	 behavior	 according	 to	 their	 physiological	
sleep-wake	 cycle.	 In	 particular,	 this	 test	 allows	 reliable	 assessment	 of	 various	 aspects	 of	
cognitive	 functions	of	mice	 in	home	cage	environment.	All	mice	 received	3	days	of	magazine	
training	 to	 familiarize	 the	 mice	 with	 reward	 delivery.	 Overall,	 the	 animals	 managed	 to	 gain	
more	than	160	pellets	per	day	before	switching	to	the	Training	phase.	During	the	training	phase	
(Fig.	4A,	B),	the	nose-poke	(NP)	activity	was	monitored;	such	activity	has	a	circadian	oscillation	
along	 the	 days	 according	 to	 the	 light/dark	 (LD)	 cycle	 (Fig.	 4C).	 The	 amount	 of	 activity	 was	
computed	with	1	hour	bin	 for	each	subject,	and	 the	periodicity,	computed	with	a	periodic	 fit	
(see	Materials	and	Methods),	was	perfectly	entrained	with	the	LD	cycle	(Fig.	4C,	boxplots	above	
the	 graph).	 The	 curves	 showed	 a	 significant	 increase	 in	 the	 NP	 activity	 for	 TAAR1-KO	 mice	
during	the	dark	phase,	suggesting	hyperactivity	during	the	night,	but	not	during	the	light	phase	
(Fig.	4C).	The	circadian	 trend	of	 the	error	 rate	was	significantly	different	within	 the	genotype	
between	the	 light	and	dark	phases	but	not	between	the	genotypes	(Fig.	4D).	 Interestingly,	by	
analyzing	error	trials	during	the	first	day	of	test,	it	was	evident	that	TAAR1-KO	mice	were	slower	
in	the	learning	of	the	test	(Fig.	4E).	During	the	first	hours	of	the	test,	when	mice	were	learning	
how	 to	 get	 the	 reward,	 TAAR1-KO	 mice	 performed	 worse	 than	 WT	 mice,	 shown	 as	 the	
difference	in	the	slope	of	the	cumulative	curve	of	error	trials	(Fig.	4E).	Later,	when	the	test	was	
learned,	 the	 slopes	 between	 the	 two	 groups	 were	 similar	 (Fig.	 4E).	 To	 further	 assess	 the	
changes	of	the	performance	over	the	light/dark	cycle,	we	analyzed	the	Actual	Inter-Trials	(AIT)	
durations	between	two	consecutive	trials.	These	intervals	occur	due	to	the	delay	of	the	mouse	
to	 initiate	 a	 trial	 and	have	been	used	 as	 a	measurement	of	 impulsivity	 (Matell	 and	Portugal,	
2007).	 A	 significant	 difference	 was	 found	 between	 genotypes	 along	 the	 24	 hours	 and	 was	
accentuated	during	the	dark	phase	(Fig.	4F).	Furthermore,	the	distribution	of	the	response	rate	
during	the	probe	trials	was	analyzed,	as	well	as	the	acquisition	of	the	START	(S1)	and	STOP	(S2)	
responses.	During	the	dark	phase,	the	S2	times	changed	significantly	across	days	(Fig.	4G),	while	
S1	times	remained	constant	and	equal	between	genotypes,	highlighting	a	perseverative	pattern	
of	behavior	in	TAAR1-KO	mice.	The	improvement	in	the	acquisition	of	the	STOP	responses	was	
evident	by	the	increase	in	the	slope	of	the	right	tail	of	the	normalized	response	rate	(Fig.	4H)	
from	the	 first	day	 to	 the	 fifth	day	of	 the	experiment.	Although	there	was	an	 improvement	 in	
STOP	responses	between	the	first	and	 last	days	 in	both	TAAR1-KO	and	WT	mice,	a	significant	
difference	 between	 the	 two	 genotypes	 remained	 throughout	 the	 experiment	 (Fig.	 4H).	
Moreover,	 the	 Peak	 times,	 which	 reflect	 the	 accuracy	 in	 the	 timing	 perception,	 were	
significantly	 different	 between	 the	 genotypes	 (Fig.	 4I)	 and	 showed	 significant	 changes	 over	
time.	 These	 changes	 in	 the	 temporal	 precision	 and	 accuracy	 (Fig.	 4G-I)	 are	 considered	 the	
hallmarks	of	the	clock-speed	adjustment	(Matell	et	al,	2006).	The	right	hopper	was	assigned	to	
the	 activation	 of	 the	 trial	 after	 a	 refractory	 period,	 the	 AIT.	 To	 further	 analyze	 impulsive	
behavior	in	these	mice,	we	analyzed	the	average	number	of	NPs	in	the	right	hopper	during	the	
AITs,	after	the	release	of	the	reward	and	along	the	24	hours	because	this	type	of	observation	
has	 also	 been	 considered	 to	 be	 related	 to	 impulsivity	 (Dalley	 et	 al,	 2004).	 According	 to	 the	
decrease	in	the	AITs,	we	observed	a	significant	increase	in	the	number	of	nose	pokes	in	KO	mice	
compared	 to	 control	 animals	 (Fig.	 4J).	 Thus,	 we	 observed	 several	 indications	 of	 cognitive	
abnormalities	 in	 mutant	 mice	 further	 supporting	 altered	 cortical	 function	 in	 mice	 lacking	
TAAR1.	
	TAAR1	agonists	reduce	impulsivity	in	mice		
To	 test	 whether	 we	 could	 modulate	 behaviors	 generally	 related	 to	 mPFC	 function	 by	
pharmacological	activation	of	TAAR1,	we	examined	the	effects	of	two	TAAR1	selective	ligands	
(Revel	 et	 al,	 2013),	 a	 full	 agonist	 and	 a	 partial	 agonist,	 RO5166017	 and	 RO5203648,	
respectively,	 (Revel	 et	 al,	 2011;	 Revel	 et	 al,	 2012)	 in	 a	 classic	 Skinner’s	 schedule	 of	
reinforcement,	 FI-30	 seconds	 (Sagvolden	 et	 al,	 1983)	 in	 C57Bl/6J	 mice.	 This	 behavioral	
paradigm	provides	a	measure	of	impulsivity	that	is	believed	to	be	at	least	in	part	controlled	by	
cortical	 function	 (Bari	 and	Robbins,	 2013).	 	 After	 training	with	 increasing	periods	of	 intervals	
(from	3	 seconds	 to	 30	 seconds),	 the	 test	 started.	 C57Bl/6J	mice	were	 injected	with	 saline	or	
TAAR1	 agonists	 before	 the	 session,	 and	 two	 parameters	 were	 scored	 as	 a	 measure	 of	
impulsivity,	 including	premature	correct	 responses	and	 the	post	 reinforcement	pause	 (Berger	
and	Sagvolden,	1998).	Pretreatment	with	RO5166017	and	RO5203648	decreased	the	number	of	
correct	 premature	 responses	 (Fig.	 5A,	 C).	 By	 analyzing	 the	 post-reinforcement	 pause,	 we	
observed	 a	 trend	 towards	 an	 increase	 in	 this	 value,	 although	 it	 did	 not	 reach	 statistical	
significance	(Fig.	5B,	D).	To	further	validate	the	target	specificity	of	these	effects	we	performed	
an	additional	experiment	with	the	highest	dose	of	RO	5203648	in	WT	and	TAAR1-KO	animals.	In	
agreement	with	previous	experiment	(Fig.	5	C,	D)	this	TAAR1	ligand	significantly	decreased	the	
premature	correct	responses	(Fig.	5E)	and	increased		post-reinforcement	pause	(5F).	In	TAAR1-
KO	mice,	the	number	of	premature	correct	responses	not	differed	from	WT	mice,	however	RO	
5203648		failed	to	exert	any	effect	on	both	parameters	in	mutant	mice	(Fig.	5E,	F).	Notably,	in	
agreement	with	previous	studies	 (Revel	et	al.,	2011;	Revel	et	al.,	2012)	 these	compounds	did	
not	exert	sedative	effect	as	indicated	by	the	analysis	of	the	total	nose	pokes	made	in	the	central	
hole	and	the	total	reinforcements	obtained	during	the	test	session	(Fig.	S3).	Both	RO5166017	
(Fig.	 S3A,	B)	 and	 RO5203648	 (Fig.	 S3C,	D)	 did	 not	 change	 significantly	 these	 parameters.	 All	
together,	 these	 data	 suggest	 that	 pharmacological	 activation	 of	 TAAR1	 in	 vivo	 modulates	
impulsivity	in	mice.	
	
Discussion	
In	this	study,	we	demonstrated	that	the	lack	of	TAAR1	results	in	reduction	of	glutamate	
NMDA	 receptor	 activity	 indicating	 that	 TAAR1	 can	 modulate	 PFC-related	 processes	 and	
behaviors.	 First,	we	observed	 that	 TAAR1	 is	 expressed	 in	 the	 PFC,	 primarily	 in	 the	 pyramidal	
neurons	 of	 layer	 V,	 supporting	 and	 extending	 the	 previous	 evidence	 on	 TAAR1	 mRNA	
expression	 in	 the	 frontal	 lobe	 (Di	 Cara	 et	 al.,	 2011).	 Furthermore,	 by	 using	 patch	 clamp	
recording	in	the	pyramidal	neurons	of	layer	V,	we	found	an	altered	response	upon	stimulation	
of	the	afferent	fibers.	From	the	analysis	of	the	eEPSC	we	noted	that	there	was	an	increase	of	
the	current	 that	potentially	may	suggest	an	 increase	 in	AMPA	receptor	activity.	 	At	 the	same	
time,	 a	 decrease	 of	 the	 current	 kinetic	 may	 suggest	 a	 decrease	 in	 NMDA	 receptor	 activity.	
Moreover,	we	found	a	decreased	NMDA/AMPA	receptors	ratio,	which	may	indicate	glutamate	
NMDA	 receptor	 hypofunction.	 The	 analysis	 of	 the	 mEPSCs	 mediated	 by	 NMDA	 revealed	 a	
strong	 reduction	 in	 the	 frequency	 and	 amplitude	 of	 the	 events,	 indicating	 indeed	 that	
postsynaptic	NMDA	receptors	 in	these	 layers	were	 less	active.	
dysfunction	of	layer	V	pyramidal	neurons	in	the	PFC	has	been	correlated	with	cognitive	deficits	
(Seamans	 et	 al,	 2001).	 It	 is	 known	 that	NMDA	 receptor	 function	 can	negatively	 affect	AMPA	
current	and	spine	formation/morphology	at	pre-	and	post-synaptic	side	(Ultanir	et	al,	2007).		In	
particular,	 NR2B	 subunit	was	 shown	 to	 inhibit	 AMPA	 receptor	 surface	 expression	 (Kim	 et	 al,	
2005).	 Thus,	 the	 increase	 of	 AMPA	 current	 observed	 in	 our	 experiments	may	 be	 potentially	
explained	by	the	reduction	of	the	NR2B	subunit	that	finely	regulates	AMPA	receptor	availability	
at	 the	postsynaptic	 side	membrane	without	 significant	changes	 in	 the	 total	amount	of	AMPA	
receptor	 protein.	 Furthermore,	 the	 decrease	 in	 NMDA	 receptor	 function	 may	 alter	 the	
presynaptic	 side	 increasing	 the	 release	of	 glutamate	 from	synaptic	 vesicles	and	 consequently	
the	AMPA	current.		
In	 an	 attempt	 to	 identify	 the	 molecular	 alterations	 that	 may	 contribute,	 at	 least	
partially,	to	such	abnormalities,	we	investigated	the	levels	and	the	phosphorylation	state	of	key	
proteins	of	the	glutamate	synapse	in	the	PFC	of	TAAR1-KO	mice.	We	found	that	the	expression	
of	GluN1	and	GluN2B	subunits	of	NMDA	receptors	was	decreased,	with	a	concomitant	decrease	
in	the	phosphorylation	site	on	the	GluN1	subunit	(S896).	This	is	of	note	given	that	GluN1	down-
regulation	has	been	linked	to	a	schizophrenia-like	phenotype	and	is	speculated	to	be	intimately	
involved	in	related	cognitive	deficits	(Mohn	et	al,	1999).	It	should	be	noted	that	while	we	have	
not	 noted	 significant	 alterations	 in	 AMPA	 receptor	 levels	 and	 phosphorylation	 we	 cannot	
exclude	an	involvement	of	AMPA	receptors	in	TAAR1-mediated	functions,	that	might	be	related	
to	potential	alterations	in	availability	of	AMPA	receptors	in	cellular	microdomains	or	in	synaptic	
versus	extrasynaptic	sites.	
These	results	were	further	corroborated	by	testing	cognitive	function	of	TAAR1-KO	mice	
in	 	 home	 cage	 environment	 in	 a	 Fixed	 Interval-Peak	 Interval	 test	 (Matell	 et	 al,	 2000).	
Particularly,	 we	 attempted	 to	 unveil	 whether	 and	which	 type	 of	 cognitive	 deficits	may	 arise	
from	TAAR1	ablation.	We	found,	 in	 fact,	 that	 the	 lack	of	TAAR1	per	sè	did	not	cause	a	global	
cognitive	 impairment	 but	 these	 mice	 were	 making	 more	 errors	 during	 the	 first	 period	 of	
learning,	 indicating	a	 small	 initial	deficit	 in	 learning.	However,	 even	more	 interestingly,	 these	
mice	displayed	an	incorrect	time	of	perception,	as	indicated	by	the	analysis	of	the	peaks	during	
probe	trials	(Coull	et	al.,	2011).	Timing	is	a	cognitive	property	well	conserved	between	species,	
and	 the	 PFC	 plays	 an	 essential	 role	 in	mediating	 the	 correct	 timing	 perception	 (Meck	 et	 al,	
2008).	 By	 analyzing	 the	 STOP	 responses	 during	 the	 probes	 trials,	 it	 emerged	 that	 TAAR1-KO	
mice	have	delayed	average	STOP	responses.	 It	 is	also	clear	 from	Fig.	4J	 that	 the	shape	of	 the	
nose-poke	distribution	between	 the	 two	genotypes	was	different,	with	a	wider	difference	on	
the	first	day	that	was	still	evident	on	the	last	day.	This	perseverative	behavior,	defined	as	a	lack	
of	 suppression	 of	 previously	 engaged	 and	 ineffective	 behavior,	 is	 a	 sign	 of	 impairment	 in	
cognitive	 flexibility	 and	 could	 be	 modeled	 by	 pharmacological	 treatments	 that	 alter	 PFC	
functions	 as	 well	 as	 by	 frontal	 cortex	 lesions	 (Floresco	 et	 al,	 2009).	 Notably,	 this	 particular	
deficit	 is	 also	 a	 phenotypic	 trait	 of	 several	 psychiatric	 diseases,	 such	 as	 schizophrenia,	
obsessive-compulsive	disorder	(OCD)	and	ADHD.	From	the	analysis	of	the	nose	pokes	during	the	
AIT	and	the	correlated	duration	of	the	AIT,	we	also	observed	a	decrease	in	the	AIT	for	TAAR1-
KO	mice	and	an	increase	in	the	nose	pokes	during	this	period,	indicating	an	impulsive	behavior	
in	mice	lacking	TAAR1.		
Furthermore,	by	using	a	classic	Skinner’s	schedule	of	reinforcement,	FI-30	seconds	test,	
a	 validated	 experimental	 paradigm	 for	 impulsivity	 in	 mice	 (Sagvolden	 et	 al,	 1983),	 we	
demonstrated	 that	 two	 selective	 TAAR1	 agonists	 (Revel	 et	 al,	 2013)	 reduced	 impulsive	
responding	 in	 normal	 mice	 thus	 indicating	 that	 stimulation	 of	 this	 receptor	 ameliorates	
impulsivity.	Impulsivity	has	also	been	generally	related	to	a	PFC	dysfunction	and	is	found	across	
several	disorders,	such	as	bipolar	disorder,	ADHD	and	addiction	(Bari	et	al,	2013).	Both	full	and	
partial	TAAR1	agonists	are	known	to	be	effective	in	reversing	hyperactivity	in	pharmacologic	or	
genetic	models	of	hyperdopaminergia	and	NMDA	deficiency	in	mice	(Revel	et	al,	2012;	Revel	et	
al,	 2013).	 Interestingly,	 TAAR1-KO	 mice	 are	 more	 prone	 to	 the	 addictive	 properties	 of	
methamphetamine,	ethanol	and	MDMA	(Achat-Mendes	et	al,	2012;	Di	Cara	et	al,	2011;	Lynch	
et	al,	2013),	while	recent	reports	from	different	groups	have	demonstrated	that	TAAR1	full	and	
partial	 agonists	 reduce	 cocaine	 conditioned	 place	 preference	 (CPP),	 self-administration	 and	
relapse	 (Pei	 et	 al,	 2014;	 Revel	 et	 al,	 2012;	 Thorn	 et	 al,	 2014a;	 Thorn	 et	 al,	 2014b).	 Since	
impulsivity	 is	 considered	 to	 be	 a	 specific	 trait	 in	 the	 pathophysiology	 of	 drug	 addiction,	 it	 is	
possible	 that	TAAR1	can	 reduce	addictive	behaviors	 in	part	 through	PFC-related	mechanisms.	
Certainly,	 more	 studies	 are	 necessary	 to	 directly	 connect	 the	 observed	 PFC	 deficits	 and	 the	
impulsive/perseverative	phenotype	of	mutant	animals.	 	Particularly,	since	TAAR1	 is	expressed	
in	 both	 the	 VTA	 dopaminergic	 nuclei	 (Lindemann	 et	 al,	 2008)	 and	 in	 the	 PFC	 (Fig.	 1A),	 the	
development	of	a	conditional	region-selective	mutant	mouse	 line	would	be	critical	to	address	
this	question.		
With	 respect	 to	 the	 mechanism	 by	 which	 TAAR1	 could	 modulate	 cortical	 glutamate	
NMDA	receptor-related	transmission	and	functions,	several	possibilities	should	be	considered.		
It	 is	 known	 that	 TAAR1	 exerts	 potent	 modulatory	 influence	 over	 mesolimbic	 dopaminergic	
system	 likely	 via	D2	dopamine	 receptor-TAAR1	heterodimerization	 (Espinoza	 et	al,	 2011)	and	
similar	mechanisms	 could	 be	 involved	 in	 the	 regulation	of	 cortical	 dopamine	 transmission	 as	
well.	 In	 this	 case,	 the	 observed	 alterations	 in	 cortical	 glutamate	 transmission	 could	 be	
secondary	to	alterations	in	cortical	dopamine	system.		Alternatively,	since	TAAR1	is	expressed	
in	 the	 layer	 V	 of	 PFC,	 where	 significant	 deficiency	 in	 NMDA	 receptor-mediated	 glutamate	
transmission	was	observed,	it	is	possible	that	glutamate	transmission	deficits	could	be	a	direct	
consequence	 of	 the	 absence	 of	 cortical	 TAAR1.	 Intriguingly,	 a	 recent	 report	 indicated	 that	
TAAR1	can	modulate	the	function	of	the	glutamate	transporter	EAAT2	leading	to	alterations	in	
glutamate	 clearance	 suggesting	 a	 direct	 connection	 between	 TAAR1	 and	 glutamate	
transmission	 (Cisneros	 and	 Ghorpade,	 2014).	 Finally,	 we	 cannot	 exclude	 an	 involvement	 of	
other	monoaminergic	systems	and	signaling	pathways	(i.e.,	serotonin-mediated,	(Lindemann	et	
al,	2008))	that	might	be	 involved	in	TAAR1-mediated	functions	and	behaviors.	Further	studies	
are	necessary	to	explore	all	these	potential	mechanisms.	
Conclusions	
In	 conclusion,	 we	 document	 here	 an	 abnormal	 PFC	 function	 in	 mice	 lacking	 TAAR1.	
Specifically,	we	found	NMDA	receptor-mediated	glutamate	transmission	deficiency	in	the	PFC,	
likely	 leading	 to	 the	aberrant	perseverative	and	 impulsive	behaviors	 that	are	observed	 in	 the	
absence	 of	 TAAR1.	 Thus,	 TAAR1-based	 drugs	 may	 provide	 a	 novel	 approach	 for	 therapeutic	
management	of	psychiatric	disorders	involving	aberrant	cortical	function.		
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Figure	legend	
	
Fig.	 1.	 Deletion	 of	 TAAR1	 increases	 the	 amplitude	 and	 kinetics	 of	 evoked	 excitatory	
postsynaptic	currents	in	layer	V	pyramidal	neurons	of	the	frontal	cortex.		
(A,	right	panel)	The	expression	of	red	fluorescent	protein	dsRed	under	the	rat	TAAR1	promoter	
in	 	 the	 layer	V	of	PFC	of	 transgenic	TAAR1	KO	dsRed	 rats.	Representative	 images	were	 taken	
using	 and	 the	 overlay	 of	 the	 bright-field	 and	 dsRed	 channel	 from	 the	 layer	 V	 of	 PFC	 of	
transgenic	TAAR1	KO	dsRed	rats	(A,	right	panel,	bottom)	and	WT	controls	(A,	right	panel,	top)	.	
(A,	 left	 panel)	 Nissl-stained	 coronal	 section	 of	 a	 brain	 slice	 containing	 the	medial	 prefrontal	
cortex	 (mPFC;	 box)	 in	 which	 patch	 clamp	 experiments	 were	 performed	 (A).	 Current-clamp	
protocol	and	representative	traces	of	action	potentials	induced	by	the	injection	of	200	pA	(B).	
Action	potential	 frequency	vs.	 injected	current	 relationship	 (F/I	 curve)	and	resting	membrane	
potential	(C),	maximal	firing	rate,	mean	firing	frequency,	current	threshold	and	input	resistance	
(D)	were	measured	in	WT	and	TAAR1-KO	mice.	(E)	Representative	traces	of	evoked	excitatory	
postsynaptic	 currents	 from	 layer	 V	 pyramidal	 neurons	 recorded	 upon	 stimulation	 of	 layer	 III	
neuron	 fibers	 in	 both	 WT	 and	 TAAR1-KO	 mice.	 (F)	 Amplitude,	 rise	 time	 and	 decay	 time	 of	
evoked	 excitatory	 postsynaptic	 currents	 were	 altered	 in	 KO	 compared	 to	WT	 neurons.	 Data	
represent	 means	 ±	 SEM.	 N=8-12	 cells	 per	 group	 and	 N=3-4	 mice	 per	 group.	 *,	 p<0.05;	 **,	
p<0.01.	Student’s	unpaired	two-tailed	t-test.	
	
Fig.	2.	TAAR1	regulates	NMDA	receptor	number/efficiency	in	layer	V	mPFC	neurons.		
Representative	 traces	 of	 evoked	 AMPA	 (-70	mV)	 or	 NMDA	 (+60	mV)	 excitatory	 postsynaptic	
currents	from	layer	V	pyramidal	neurons	recorded	upon	stimulation	of	 layer	 III	 fibers	(A).	The	
NMDA/AMPA	 ratio	 decreases	 in	 TAAR1-KO	 neurons	 with	 respect	 to	 WT	 neurons	 (B).	
Representative	traces	of	miniature	NMDA	excitatory	postsynaptic	currents	from	both	WT	and	
TAAR1-KO	layer	V	mPFC	neurons	(C).	TAAR1-KO	neurons	show	a	decrease	in	NMDA	miniature	
post-synaptic	current	amplitude	and	frequency	(D,	E).	Data	represent	means	±	SEM.	N=6-10	per	
group	N=3-4	mice	per	group.	**p<0.01	Student’s	unpaired	two-tailed	t-test.	
	
Fig.	3.	NMDA	receptor	composition	is	altered	in	the	prefrontal	cortex	of	mice	lacking	TAAR1.	
Western	blot	densitometric	analysis	of	 the	prefrontal	cortex	extracts	 from	WT	and	TAAR1-KO	
mice.	Synaptosomal	fractions	were	separated	from	the	whole	lysate	and	then	analyzed	by	gel	
electrophoresis.	Antibodies	against	GluN1	(A),	p-S896-	GluN	1	(A),	p-S897-	GluN	1	(A),	GluN	2B	
(B),	p-S1303-	GluN	2B	(B),	GluN	2A	(B),	GluA1	(C),	p-S831-GluA1	(C)	and	PSD-95	(C)	were	used.	
Actin	was	used	as	the	loading	control	for	the	densitometric	analysis.	Results	were	normalized	to	
their	respective	WT	controls.	Data	represent	means	±	SEM.	N=10-15	per	group.	*,	p<0.05;	**,	
p<0.01.	Student’s	unpaired	two-tailed	t-test.	
	
Fig.	4.	TAAR1-KO	mice	display	perseverative	and	impulsive	behaviors	in	home	cage.	Graphical	
representation	of	the	task.		Fix-Interval	(FI)	task	(A)	present	two	hoppers	(right	“R”	and	left	“L”)	
in	which	a	light	signal	of	two	seconds	(L=2)	declares	the	start	of	the	trial.	The	target	time	(T)	is	
fixed	 to	 10	 seconds.	 The	 probability	 of	 trial	 to	 occur	 in	 “L”	 location	 is	 100%	 (P(L)=1).	 Peak-
Interval	 (PI)	 task	(B)	 introduces	probe	trials	 (Lp)	 that	are	randomly	 intermixed	to	normal	trials	
with	20%	of	probability	(P(Lp)=0.2)	to	occur	(left	panel).	Example	of	normalized	response	curve	
during	probe	trials	(right	panel)	.	The	circadian	profile	of	the	nose-poke	(NP)	activity	(C)	exhibits	
significant	genotype	(Two-way	ANOVA:	F(1,143)=13.71,	***p<0.001)	difference	during	the	dark	
phase	(19-7	h).	 (C).	Boxplots	above	the	curves	show	no	difference	 in	the	circadian	periodicity	
for	 WT	 and	 TAAR1-KO	 mice	 (C).	 The	 circadian	 trend	 of	 the	 error	 rate	 (D)	 was	 significantly	
different	 within	 genotype	 and	 between	 light	 and	 dark	 phases	 (Two-way	 ANOVA	 for	 WT:	
F(1,143)=40.67,	 p<0.001;	 for	 KO:	 F(1,143)=64.96,	 p<0.001),	 but	 not	 between	 genotypes	
(F(1,287)=0.47,	 p=0.49)	 as	 summarized	 in	 the	 histogram	 above	 the	 curve.	 Cumulative	
distribution	function	(CDF)	of	the	error	rate	along	the	time	(E).	Significant	difference	of	the	total	
errors	between	genotypes	during	the	first	three	hours	of	the	first	dark	phase	(19-21),	p=0.04.	
No	difference	between	genotypes	 in	the	subsequent	 intervals	 (p≥0.05).	Analysis	of	the	Actual	
Inter	 trials	 (AITs)	 (F)	 revealed	 a	 difference	 between	 genotypes	 along	 24	 hours	 (Two-way	
ANOVA:	 F(1,287)=4.5,	 p=0.03)	 that	 was	 accentuated	 during	 the	 dark	 phase	 (F(1,143)=8.81,	
p=0.003).	Bonferroni	post-hoc	analysis	does	not	 revealed	significant	difference	between	each	
time	point.	Analysis	of	START	(S1)	and	STOP	(S2)	responses	(G).	During	the	dark	phase,	the	STOP	
times	changed	significantly	across	days	(Two-way	ANOVA:	F(4,56)=3.64,	p=0.01).	The	genotype	
effect	was	also	significant	 (F(1,59)=5.35,	p=0.02).	There	was	no	difference	 in	 the	START	 time.	
Normalized	 response	 rate	 during	 probe	 trials	 in	 the	 first	 and	 last	 days	 (H).	 Peak	 times	were	
significantly	 different	 between	 genotypes	 (F(1,59)=4.19,	 p=0.04)	 and	 showed	 significant	
changes	over	time	(F(4,56)=3.05,	p=0.02)	(I).	The	right	nose	pokes	during	the	AITs,	along	the	24	
hours,	 revealed	 a	 difference	 between	 genotypes	 (F(1,96)=4.44,	 p=0.03)	 (J).	 All	 the	 data	 are	
shown	as	mean±SEM	per	group	(N=6	per	group	for	both	WT	and	TAAR1-KO	mice).	*	p<0.05;	**	
p<0.005;	***	p<0.001.	
	
	
	
Fig.	 5.	 Systemic	 administration	 of	 selective	 TAAR1	 agonists	 reduces	 impulsivity	 in	 a	 FI	 30	
second	 test	 in	 normal	 mice	 RO5166017	 and	 RO5203648	 decreased	 the	 number	 of	 correct	
premature	responses	in	C57Bl/6J	mice.	((A,	C);	F(3,28)=4.078	p<0.05	and	F(3,26)=8.029	p<0.05,	
respectively).	Post	hoc	analyses	(Bonferroni’s	test)	revealed	that	this	TAAR1	agonist	effect	was	
statistically	significant	at	the	dose	of	1.0	mg/kg	for	RO5166017	and	at	the	doses	of	0.1	and	0.3	
mg/kg	 for	 RO5203648.	 Activation	 of	 TAAR1	 receptors	 did	 not	 affect	 significantly	 post-
reinforcement	pause	(F(3,28)=1.967	p=0.14;	F(3,26)=2.506	p=0.08,	RO5166017	and	RO5203648	
respectively)	(B,D).	All	the	data	are	shown	as	mean±SEM.	N=12	per	group.	RO5203648	at	dose	
0.3	mg/kg	was	able	to	reduce	the	number	of	correct	premature	responses	in	WT	(p<0.05)	but	
not	in	TAAR1-KO	animals	(E).	Similarly,	RO5203648	increased	post-reinforcement	pause	in	WT	
(p<0.01)	but	not	in	TAAR1-KO	mice	(F).	All	the	data	are	shown	as	mean±SEM.	N=10	(WT)	and	8	
(KO)	per	group	.	*,	p<0.05;	**,	p<0.01.	One	way	ANOVA	with	Bonferroni	post	hoc	test.	
